Blood Podcast Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors
Aug 29, 2024
Late relapses in younger patients with mantle cell lymphoma and what those outcomes look like. Mass spectrometry monitoring of M‑protein in peripheral blood during multiple myeloma maintenance. Experimental in vivo CAR T‑cell generation in nonhuman primates using lentiviral vectors targeting CD19.
AI Snips
Chapters
Transcript
Episode notes
Mass Spectrometry Detects M-Protein During Maintenance
- Mass spectrometry can detect M-protein in peripheral blood during maintenance, offering sensitive monitoring for multiple myeloma.
- The episode references MS-based M-protein assessment as an alternative to conventional methods during maintenance therapy.
Late Relapse Occurs Despite Modern MCL Therapy
- Younger mantle cell lymphoma patients relapse beyond 24 months despite modern regimens including high-dose cytarabine and BTK inhibitors.
- The LATE-POD study highlights late relapses even after therapies like rituximab-bendamustine and ibrutinib, changing long-term follow-up expectations.
In Vivo CAR T Cells Made With VivoVec Lentivirus
- In vivo CAR T generation was achieved in nonhuman primates using lentiviral vectors with a multidomain fusion ligand.
- The VivoVec platform enabled in vivo transduction of CD19-positive cells, showing feasibility before CRISPR-Cas discussions.